Wednesday, August 27, 2014

Web Seminar: Drug Development in Alzheimer’s Disease: Reasons to Remain Optimistic

In coordination with PRA Health Sciences, ahead of World Alzheimer's Day, we're pleased to announce the following web seminar:

Web Seminar: Drug Development in Alzheimer’s Disease: Reasons to Remain Optimistic
Date: Thursday, September 18, 2014
Time: 10:00 AM - 11:00 AM EDT
Register to join us.
Mention proirity code XP2000W1BLOG

About the web seminar:
US prevalence of Alzheimer’s Disease is currently at 5 million sufferers and is set to triple by 2050. Subsequently, the quest for new symptom and disease modifying treatments is intense. Unfortunately, with more than 100 efforts to develop potential therapies in the past 15 years, only cholinesterase inhibitors and memantine have received marketing authorization, and their value as symptom treatments is considered modest at best. With a projected cost to care for all Alzheimer’s patients by 2050 expected to exceed $1 billion, continued failure to find treatments may not be a financial option, as such an outcome would threaten the sustainability of health insurers including Medicare and Medicaid.

Despite the tremendous number of failures in Alzheimer’s drug development, each of these efforts have been instructive,and there remain close to 100 compounds either in or close to being ready for human testing. The missteps of the past are enlightening some different paths forward, and while the majority of compounds in trials remain focused on the traditional amyloid models of pathophysiology, newer efforts are focused on more upstream pathways, vaccines and gene therapy. Additionally, some of the most exciting possibilities are trials focused on the at risk asymptomatic and mildly symptomatic populations, the work of the Alzheimer’s Prevention Initiative, the DIAN Network, and the funding being provided through the NAPA.

What you will learn:
1) Review of disease state and prevalence
2) Current thinking on pathophysiology and drug targets
3) Drug development review of the most promising compounds
4) Challenges to recruitment and conduct of global AD trials
5) The new focus on Alzheimer’s prevention in clinical trials

Frederick T. Lewis, D.O., Vice President Neurosciences, Scientific Affairs at PRA Health Sciences

Mention proirity code XP2000W1BLOG

PRA Healthsciences is a partner of the Partnerships in Clinical Trials Conference. Partnerships will take place April 22-24, 2015 in Boston. To stay up to date on the latest news about the upcoming event, sign up to receive email updates.

No comments: